We are live on ! Find out more
BIOT

Biotech Acquisition Company Class A Ordinary Shares
BIOT

Delisted

BIOT was delisted on the 2nd of February, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in Biotech Acquisition Company Class A Ordinary Shares in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 68 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 68 → 0 (-68)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

100% less capital invested

Capital invested by funds: $226M → $0 (-$226M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 68

Holders
–
Holders Change
-68
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
68
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
GCL
Glazer Capital LLC
New York
-$23.1M
2
AC
Aristeia Capital
Connecticut
-$15.4M
3
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$12.7M
4
Marshall Wace
Marshall Wace
United Kingdom
-$10.2M
5
SCM
Saba Capital Management
New York
-$9.75M
Name Holding Trade Value Shares
Change 		Change in
Stake
CCA
51
Castle Creek Arbitrage
Colorado
– -$505K -50,000 Closed
COPPSERS
52
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
– -$505K -50,000 Closed
SCM
53
Segantii Capital Management
Hong Kong
– -$505K -50,000 Closed
Janus Henderson Group
54
Janus Henderson Group
United Kingdom
– -$423K -41,862 Closed
E
55
Ergoteles
New York
– -$422K -41,773 Closed
LA
56
Linden Advisors
New York
– -$404K -40,008 Closed
GAM
57
Gritstone Asset Management
Maryland
– -$396K -39,247 Closed
LCM
58
Landscape Capital Management
New Jersey
– -$389K -38,501 Closed
FTCM
59
First Trust Capital Management
Illinois
– -$365K -36,183 Closed
Bank of America
60
Bank of America
North Carolina
– -$252K -25,000 Closed
KIM
61
Karpus Investment Management
New York
– -$252K -25,000 Closed
WP
62
Woodline Partners
California
– -$252K -25,000 Closed
DFCM
63
Dark Forest Capital Management
Puerto Rico
– -$191K -18,954 Closed
DIG
64
DeepCurrents Investment Group
New York
– -$179K -17,730 Closed
SOA
65
Sea Otter Advisors
Florida
– -$151K -15,000 Closed
SIA
66
SkyView Investment Advisors
New Jersey
– -$32K -3,183 Closed
EC
67
Elequin Capital
New York
– -$15.3K -1,510 Closed
CS
68
Clear Street
New York
– -$2K -227 Closed
1 2
3

BIOT Hedge Fund Activity: Q1 2023 in Review

0 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Class A Ordinary Shares (BIOT) for Q1 2023, worth a combined $0 — down 100% from $226M a quarter earlier.

Sellers outnumbered buyers: 68 funds closed out of BIOT and 0 opened new positions — a net loss of 68 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Glazer Capital LLC, exiting entirely with an estimated $23.1M sold.

  • 0 institutional investors held Biotech Acquisition Company Class A Ordinary Shares (BIOT) as of Q1 2023, down from 68 in Q4 2022.
  • Funds reported $0 of Biotech Acquisition Company Class A Ordinary Shares stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Biotech Acquisition Company Class A Ordinary Shares positions in Q1 2023 and 68 closed out, a net change of -68 holders.
  • The largest Biotech Acquisition Company Class A Ordinary Shares seller in Q1 2023 was Glazer Capital LLC, an estimated $23.1M sold.

Based on aggregated 13F filings for Q1 2023.